Zobrazeno 1 - 10
of 163
pro vyhledávání: '"C C Benz"'
Autor:
C C Benz
Publikováno v:
Endocrine Related Cancer. 5:271-282
Autor:
C. C. Benz, T. J. Ormsby, A. J. Rogers, Maria Elizabeth Tiritan, X. S. Liang, C. L. Webber, S. A. Matlin
Publikováno v:
Investigational New Drugs. 13:181-186
Preclinical and clinical studies have pointed to the antitumor potential of the naturally occurring polyphenolic binaphthyl dialdehyde, gossypol, as well as its purified (-,+) enantiomers. To explore further the antitumor properties of this multifunc
Autor:
J M W, Gee, A, Howell, W J, Gullick, C C, Benz, R L, Sutherland, R J, Santen, L-A, Martin, F, Ciardiello, W R, Miller, M, Dowsett, P, Barrett-Lee, J F R, Robertson, S R, Johnston, H E, Jones, A E, Wakeling, R, Duncan, R I, Nicholson
Anti-hormones (notably tamoxifen), chemotherapy and modern radiotherapeutic approaches are invaluable in the management of breast cancer, and collectively have contributed substantially to the improved survival in this disease. Moreover, there is pro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::33fd787caa7ac4036efdf81f1251e916
http://hdl.handle.net/11591/227189
http://hdl.handle.net/11591/227189
Publikováno v:
Advances in gerontology = Uspekhi gerontologii. 11
This review and study of nearly 4,000 primary breast cancers evaluates the hypothesis that human aging not only increases breast cancer incidence but also alters breast cancer biology. Clinically validated biomarkers were chosen as surrogate measures
Publikováno v:
Vitamins and hormones. 60
Liposome-encapsulated anticancer drugs reveal their potential for increased therapeutic efficacy and decreased nonspecific toxicities due to their ability to enhance the delivery of chemotherapeutic agents to solid tumors. Advances in liposome techno
Autor:
F K Guerra-Vladusic, Valerie M. Weaver, E A Vladusic, C C Benz, Miaw Sheue Tsai, Ruth Lupu, G Scott
Publikováno v:
Scopus-Elsevier
We have previously reported that Heregulin (HRG)/neu differentiation factor (NDF) induced growth arrest and cellular differentiation in breast cancer cells overexpressing erbB-2 receptor. To elucidate the cellular mechanisms underlying the growth inh
Autor:
J, Baselga, D, Tripathy, J, Mendelsohn, S, Baughman, C C, Benz, L, Dantis, N T, Sklarin, A D, Seidman, C A, Hudis, J, Moore, P P, Rosen, T, Twaddell, I C, Henderson, L, Norton
Publikováno v:
Seminars in oncology. 26(4 Suppl 12)
The HER2/neu proto-oncogene is overexpressed in 25% to 30% of patients with breast cancer. Trastuzumab (Herceptin; Genentech, San Francisco, CA), a recombinant humanized monoclonal antibody with high affinity for the HER2 protein, inhibits the growth
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 5(2)
Human breast tumors that are initially responsive to tamoxifen (TAM) eventually relapse during treatment. Estrogen receptor (ER) expression and function are often preserved in these tumors, and clinical evidence suggests that this relapse may be rela
Publikováno v:
Cancer research. 57(17)
Preliminary studies have suggested that measuring the ability of immunoreactive 67-kDa estrogen receptor (ER) to bind DNA and form in vitro complexes with its cognate estrogen response element (ERE) might serve to identify breast tumors most likely t
Autor:
C C, Benz
Publikováno v:
The Western journal of medicine. 164(2)